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8SUMMARY
FMS-like tyrosine kinase 3 (FLT3) is a commonly mutated gene found in acute myeloid
leukaemia (AML) patients and activated FLT3 is a promising molecular target for AML
therapies. My data so far has shown that the green tea polyphenol (−)-epigallocatechin-3-
gallate (EGCG) suppresses cell proliferation, inducing apoptosis in AML cells with FLT3
mutations. Interestingly, I found that EGCG has the ability to down-regulate the expression
of FLT3 and suppress the activity of its downstream signalling molecules such as AKT,
MAPK and STAT5 [1]. However, the exact mechanism underlying FLT3 regulation by
EGCG has not been completely clarified. In 2009, Yin et al. demonstrated that EGCG is a
potential heat shock protein (Hsp) 90 inhibitor [2]. Moreover, mutant FLT3 has been found
to be a bona fide client protein for Hsp90 in cell models and primary AML cells [3,4].
However, the chaperoning role of Hsp90 towards wild-type (WT) FLT3 is still
controversial. Thus, the aims of my research are: (1) investigating the involvement of Hsp90
in the down-regulation of FLT3 levels by EGCG, (2) investigating the influence of EGCG
on FLT3 promoter activity and gene expression and (3) evaluating the combination effect of
EGCG and PKC412 (an FLT3 inhibitor) on AML cells with FLT3 mutations..
First, I clarified whether FLT3-WT requires Hsp90 as a molecular chaperone. The results
showed that endogenous FLT3-WT was not co-IP with Hsp90 in THP-1 cells, but ectopic
FLT3-WT expressed in 293FT was able to form a complex with Hsp90. Moreover, I found
that endogenous FLT3-WT in THP-1 cells was not phosphorylated, whereas ectopically-
expressed FLT3-WT in 293FT was phosphorylated. Using FLT3-WT/ITD/D835V-K644R
mutants, which are constitutively de-phosphorylated, were not co-IP with Hsp90 in 293FT
cells. These data indicated that Hsp90 selectively interacts with phosphorylated FLT3.
9Upon confirming that Hsp90 selectively binds to phosphorylated FLT3, I postulated that the
suppression of cellular FLT3 levels by EGCG is mediated through the inhibition of Hsp90
function by EGCG. Indeed, EGCG disrupted the interaction between Hsp90 and FLT3 in
293FT and MOLM-13 cells. Interestingly, the stability of endogenous FLT3-WT in THP-1
cells was not significantly influenced by EGCG treatment; I assume that this is mainly
because FLT3-WT was not phosphorylated in THP-1 and thus there was no binding to
Hsp90.
In contrast to EGCG, studies on other polyphenols such as ECG, EGC and catechin and the
mechanism of underlying their biological activities have rarely been reported. In this study, I
suggest for the first time that EGC and ECG but not catechin suppress FLT3 expression by
inhibiting Hsp90 function in the same manner as that followed by EGCG.
I also found that EGCG reduced the transcription level of FLT3 by suppressing its promoter
activity.
Moreover, I obtained effective FLT3 down-regulation with a physiological serum
concentration of EGCG (<10μM) on the combination with PKC412. For example, when
combined with the FLT3 inhibitor- PKC412, the concentration of EGCG decreased to 10
µM (with 5 nM PKC412) and even 5 µM (with 7 nM PKC412) in MOLM-13 cells,
suggesting that there exists a suitable strategy for using EGCG in clinical treatment.
Taken together, I clarified that EGCG, EGC and ECG destabilized FLT3 by disrupting its
interaction with Hsp90. I have provided evidence that EGCG suppresses FLT3 promoter
activity and its transcription. Thus, I propose that EGCG could be a useful therapeutic agent
for AML patients, particularly when used in combination with other drugs such as the FLT3
inhibitor, PKC412.
10
INTRODUCTION
1. FMS-like tyrosine kinase 3
1.1. FMS-like tyrosine kinase 3 receptor
FMS-like tyrosine kinase 3 (FLT3) is a commonly mutated gene in acute myeloid leukaemia
(AML) [5]. Approximately 30 % AML patients harbour a FLT3 mutation [5]. FLT3 belongs
to the class III receptor tyrosine kinase (RTK) family, along with the stem cell (Steel) factor
receptor (KIT), macrophage colony-stimulating factor (M-CSF), receptor-FMS and the
platelet-derived growth factor receptors PDGFRα and β. FLT3 shares approximately 30%
homology with other family members. The FLT3 gene was isolated using placenta cells by
Rosnet et al. in 1991 [6,7] and cloning of the human FLT3 gene followed a few years later
[8]. At the same time, another group identified FLT3 from murine-enriched stem cell
population of foetal liver cells and termed it foetal liver kinase-2 (Flk-2) [9]. The sequence
of human FLT3 is homologous to murine FLT3. The human FLT3 gene is located on
chromosome 13q12 and encompasses 24 exons. It encodes a membrane-bound glycosylated
protein of 993 amino acids with a molecular weight of 158–160 kDa, as well as a non-
glycosylated isoform of 130–143 kDa, which is not associated with the plasma membrane
[7,10]. Similar to other members of the class III RTK family, FLT3 is characterized by an
extracellular domain consisting of five immunoglobulin-like domains, a single
transmembrane region, a cytoplasmic juxtamembrane domain (JMD) and a cytoplasmic
tyrosine kinase domain (TKD) interrupted by a kinase insert domain (Fig. 1A) [11-14].
FLT3 receptor is normally expressed on the cell surface of haematopoietic progenitor cells,
but its expression is lost upon cell maturation [15]. The expression of FLT3 has been also
detected in the brain, bone marrow, placenta and gonads, where its function is unknown
11
[6,9,15]. FLT3 expression can be found in different human and mouse cell lines of both
myeloid and lymphoid lineages, but the distribution is quite different [16-18]. Many studies
indicate that FLT3 has a crucial role in the development, survival and proliferation of
normal stem/progenitor cells [19].
Recent studies have indicated that approximately 10%–15% AML patients display high
expression of wild-type (WT) FLT3 [20]. High FLT3 expression has a negative impact on
overall and event-free survival in cytogenetically normal AML (CN-AML) patients lacking
FLT3 mutations [21].
1.2. FLT3 ligand
FLT3 ligand (FL), first cloned in 1993-1994 by two independent groups [22,23], is one of
the most important early-acting haematopoietic cytokines contributing to the maintenance,
expansion and differentiation of haematopoietic stem cells [24]. FL is expressed as
transmembrane molecules or remain attached to extracellular matrix components and can be
converted to soluble factors by proteolytic processing or shedding, thus serving the need for
local control of HSC stimulation [24,25]. Alternative splicing contributes to the generation
of a soluble FL isoform by a stop codon inserted into the reading frame of the sixth exon
[25]. Despite the widespread expression of FL mRNA in both haematopoietic and non-
haematopoietic tissues [22,26], the FL protein has only been found in stromal fibroblasts
present in the bone marrow microenvironment and T lymphocytes [27]. Both the membrane-
bound and soluble isoforms of FL are biologically active and stimulate the tyrosine kinase
activity of FLT3 [25]. Mice lacking FL as a result of targeted gene disruption are viable but
have more severe defects than FLT3 receptor knockouts, including reduced cellularity in the
haematopoietic organs, reduced number of myeloid and lymphoid progenitors in the bone
marrow and a marked deficiency of natural killer and dendritic cells in the lymph nodes,
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spleen and thymus [28]. The co-expression of FL and FLT3 found in 40 of 110 cell lines
indicated that the native FLT3 and FL may play a role in the survival or proliferation of
leukaemic blasts [29].
1.3. FLT3 mutations in AML
Nakao et al. first reported the presence of internal tandem duplications (ITDs) in the JM of
FLT3 in AML and suggested that these mutations play an important role in AML
pathogenesis [30]. FLT3-ITD occur in approximately 25% younger adult patients with AML,
predominantly in CN-AML [31]. ITD mutations result in amino acid sequence changes with
intact coding frame that lead to a constitutive activation of FLT3, its downstream signalling
pathways and dysregulation of cellular proliferation [32-34]. ITDs are located in exons 14
and 15 of FLT3 and show a broad variation in the position of their insertion sites, from three
to several hundred base pairs, with variable start and end points-, as well as in the number
and sizes of the duplicated fragments [35-38]. The term ‘FLT3-ITD’ was derived from the
attribute of an ‘internal tandem duplication’ but in reality, ‘ITDs’ can also include insertions
of random extra nucleotides or be sole insertions of foreign sequences; therefore, a more
appropriated term, ‘length mutation’ (FLT3-LM), was suggested [39]. It was previously
assumed that FLT3-ITD localized in the JMD of FLT3, but Breitenbuecher et al. (2009)
reported that approximately 30% FLT3-ITDs are situated in non-JMDs as well [38]. In 2001,
the gain-of-function- missense point mutations in the activation loop domain of TKD of the
FLT3 receptor (FLT3-D835) was first described at a frequency even lower than that of
FLT3-ITD mutations—the mutations were from D835 to Y or H, or less frequently to V or
E [40,41]. Subsequently, other FLT3 point mutations were also found in others domains
including JMD, TKD1 particularly the secondary FLT3 point mutations that convey
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resistance to FLT3 inhibitors [35,42,43]. FLT3-TKD point mutations occur in
approximately 5%–10% AML patients [35,42].
Clinically, FLT3-ITD occurs most frequently in CN-AML, trisomy 8, t(6;9) and t(15;17),
[39,44] and it is generally associated with leukocytosis on presentation [45-47]. While there
are diverging data concerning the prognostic implications of FLT3-TKD [46,48,49], many
studies have uniformly supported the view that the presence of FLT3-ITD is a major
independent adverse prognostic indicator, associated with an increased risk of relapse and
worse overall survival [37,44,50] particularly in those with high FLT3-ITD allelic ratios that
predict for  low complete remission rates and poor survival [35,51,52].
1.4. FLT3-mediated signal transduction pathways
Upon stimulation by FL, FLT3-WT promotes receptor dimerization and subsequent
signalling (Fig. 1B) through tyrosine-phosphorylated GAP, PLCg, Vav, Shc, and the p85
subunit of phosphoinositide-3 kinase (PI3K) and associate with GRB2, GAB2, SHIP, SHP2
(a protein tyrosine phosphatase), CBL (a proto-oncogene) and CBLB (a CBL-related
protein) that ultimately act on the p85 subunit of PI3K [53-56]. FLT3 and these adaptor-
protein complexes probably stimulate downstream effectors in the RAS–RAF–mitogen-
activated protein/extracellular signal-regulated kinase (MEK)–extracellular-regulated kinase
(ERK) pathway and PI3K pathway [54,55,57] (Fig. 2). Activated PI3K subsequently leads
to the activation of a protein kinase cascade, including protein kinase B (PKB), mammalian
target of rapamycin (mTOR), and p70-ribosomal-S6-kinase (SK6) [58]. FLT3-WT also
causes phosphorylation of mitogen-activated protein kinase (MAPK) and minimal cell
growth on FL stimulation in interleukin-3 (IL-3)-dependent haematopoietic progenitor
Ba/F3 cells [54]. Consequently, both pathways have a strong inﬂuence on the regulation of
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transcription [59] and/or translation [via the 90 kDa ribosomal S6 kinase (RSK) or
mTOR/S6K] [58,60] of multiple regulatory genes.
FLT3-ITD and FLT3-TKD are constitutive activation proteins [61] (Fig. 1C and D).
Together with modulating crucial downstream signal transducers such as Ras and MAPK,
FLT3-ITD induces the activators of transcription, such as the signal transducer and activator
of transcription 5 (STAT5) [32,33] (Fig. 2).
1.4.1.Negative regulation of FLT3 by the adaptor protein Lnk
Lnk (also known as SH2B3) is expressed in haematopoietic cells and plays a critical role in
cytokine signaling and haematopoiesis [62-64]. Along with SH2-B (SH2B1) and APS
(SH2B2), Lnk belongs to a family of adaptor proteins that modulate signalling of several
cytokine and growth factor receptors. [65,66]. Lnk negatively modulates several important
cytokine-induced signalling pathways, including the SCF/c-KIT, erythropoietin/JAK2 and
thrombopoietin (TPO)/MPL-JAK2 pathways [63,67-69]. Lnk interacts with JMD,
speciﬁcally to p-Tyr568 of c-KIT [70] and binds to PDGFRA, PDGFRB and FMS [71,72].
Interestingly, Lnk was found to physically interact with both FLT3-WT and FLT3-ITD
through SH2 domains [73]. The tyrosine residues 572, 591, and 919 of FLT3 as
phosphorylation sites are involved in direct binding to Lnk. Lnk itself is tyrosine
phosphorylated by both FL-activated FLT3-WT and constitutively activated FLT3-ITD. It
has been demonstrated that both shRNA-mediated depletion and forced over-expression of
Lnk results in activation signals that emanate from both the forms of FLT3 and are under
negative regulation by Lnk. Moreover, Lnk inhibited 32D cell proliferation driven by
different FLT3 variants. Analysis of primary BM cells from Lnk-knockout mice showed that
Lnk suppresses the expansion of FL-stimulated haematopoietic progenitors, including
lymphoid-primed multipotent progenitors [73].
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1.4.2.FLT3 is transactivated by spleen tyrosine kinase
Spleen tyrosine kinase (SYK) is a cytoplasmic tyrosine kinase critical in normal B cell
development and haematopoietic signalling [74]; it was recently found to be aberrantly
activated through translocations in T cell lymphoma [75] and myelodysplastic syndrome
[76]. In 2014, Puissant et al. found that FLT3 is transactivated by SYK via direct binding
[77].  This study demonstrated that FLT3-ITD was dependent on SYK for driving myeloid
neoplasia in mice, despite the constitutive activation of the FLT3 receptor. Highly activated
SYK is predominantly found in FLT3-ITD-positive AML and cooperates with FLT3-ITD to
activate MYC transcriptional programs. Furthermore, activated SYK does not exert the
same pro-oncogenic effect on other tyrosine kinase oncogenes, such as BCR-ABL, as it does
on FLT3-ITD. However, the mechanism underlying SYK activation in FLT3-ITD-positive
AML remains uncertain. FLT3-ITD AML cells are more vulnerable to SYK suppression
than FLT3-WT counterparts. In an in vivo study of FLT3-ITD function, SYK was reported
to be indispensable for myeloproliferative disease development, and SYK over-expression
promoted overt transformation to AML and resistance to FLT3-ITD-targeted therapy [77].
1.4.3.Mutant FLT3 is stabilized by heat shock protein 90
Heat shock protein 90 (Hsp90) is one of the most abundant chaperone proteins in cells,
comprising 1%–2% cellular proteins under non-stress conditions [78]. It interacts with a
large and diverse group of substrate proteins; it interacts with almost 400 proteins including
human kinases, transcription factors, and E3 ligases, commonly referred to as ‘clients’,
promoting their folding and function [79]. Hsp90 seemingly focuses on metastable proteins
that are regulatory hubs in biological networks [80].
Mutant FLT3 has been demonstrated to be a bona fide client protein for Hsp90 in cell
models and primary AML cells [3,4,81,82]. Hsp90 inhibitors including herbimycin A (HA);
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17-allylaminodemethoxygel danamycin (17-AAG), geldanamycin were shown to disrupt the
chaperone association of Hsp90 with mutant FLT3 resulting in the degradation of FLT3-ITD
and apoptosis of myeloid cell lines transfected with mutant FLT3 as well as of primary
AML cells expressing FLT3-ITD [1,3,4,81-83]. However, in the literature, for the
chaperoning of FLT3-WT by Hsp90 is still a controversial topic. The results obtained using
32D/FLT3-WT cells [81] and AML blasts [3] showed that FLT3-WT did not bind to Hsp90.
The absence of FLT3-WT from the Hsp90-immunoprecipitated complex in FLT3-WT AML
blasts was assumed to be not because of its low expression but perhaps because of Hsp90
having a low affinity for FLT3-WT [3]. On the other hand, others reports indicated that
Hsp90 could form a complex with FLT3-WT in SEMK2 leukaemic cells, Ba/F3 and 32D
expressing FLT3-WT [4,82].
1.5. Transcriptional regulation of FLT3 expression
The transcription of FLT3 is regulated by Hoxa9, Meis1, c-Myb and C/EBPα [84-86].
Hox proteins are homeodomain-containing transcription factors that play a vital role in
establishing body plan during development, limb regeneration, wound healing, adipogenesis,
and haematopoietic stem cell self-renewal [87]. Hoxa9 in particular is expressed at high
levels in early haematopoietic progenitor cells and promotes stem cell expansion; in contrast,
Hoxa9 down-regulation is associated with haematopoietic differentiation [88,89]. The Hox
cofactor- Meis1 cooperates with Hox genes to accelerate the onset of AML in mouse models
[90]. Interestingly, Meis1 is frequently found to be up-regulated along with Hox genes in
human leukaemias, and this is associated with particularly high levels of FLT3 mRNA [91].
Chromatin immunoprecipitation (IP) has been used to conﬁrm co-occupancy of Hoxa9 and
Meis1 on the FLT3 promoter in myeloid leukaemogenesis and lymphohaematopoietic
models [84-86]. Hoxa9 knockdown has been reported to signiﬁcantly reduce FLT3
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transcription and expression [84]. Conversely, forced expression of Hoxa9 was found to
increase FLT3 transcription and expression in a Pro-B cell line that expressed low levels of
FLT3 [84].
The CCATT/enhancer-binding protein alpha (C/EBPα) is a leucine zipper transcription
factor that has a pivotal role in granulocyte and neutrophil development [92] and also acts as
a tumours suppressor in the haematopoietic system [93]. So far, a few hints of a connection
between FLT3 and C/EBPα markers have been demonstrated [94,95]. These studies showed
that the favourable outcome associated with bi-allelic C/EBPα mutations was cancelled out
by the presence of FLT3-ITD mutations [94,95]; FLT3-ITD signalling inhibits C/EBPα
differentiating function by promoting C/EBPα phosphorylation [96], and C/EBPα with a C-
terminal mutation collaborates with FLT3-ITD in inducing AML [97]. Such collaborations
may rely on the ability of FLT3 signalling to support myeloid commitment of the expanding
C/EBPα-mutated cells [94]. A study pertaining to the proﬁling arrays from AML patients
with differing C/EBPα status linked FLT3 expression and C/EBPα activity and also showed
that bi-allelic C/EBPα mutations associated with lower levels of FLT3 transcript in AML
patients, whereas no signiﬁcant differences in FLT3 expression between patients with WT
or mono-allelic C/EBPα mutations were noted [86].
c-Myb is a leucine zipper transcription factor; its expression is associated with immature and
proliferative cellular stages and turned off during the maturation of the haematopoietic
lineage [98,99]. Silencing strategies in mice have shown that c-Myb plays a major role in
haematopoiesis, including lineage commitment, proliferation and differentiation [100-103].
c-Myb activity also associates with a broad spectrum of haematological malignancies,
including chronic myeloid leukaemia, T-acute lymphoblastic leukaemia and AML [104-106].
c-Myb has a critical role in the transforming potential of the AML-inducing fusion protein
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MLL-ENL [106]. Notably, c-Myb was identified as an important downstream target of
Hoxa9 and Meis1 [106]. The cooperative activities of c-Myb and C/EBPα in activating the
promoter of myeloid genes including FLT3 have been previously reported [86,107,108].
Together with Hoxa9 and Meis1, C/EBPα and c-Myb are important elements of the
combinatorial binding of leukaemia-related transcription factors that regulate FLT3
expression [86].
The transcription factor hairy and enhancer of split 1 (Hes1) was recently found to directly
bind to the promoter region of the FLT3 gene and down-regulated its promoter activity [109].
FLT3 was consequently up-regulated in MLL–AF9-expressing immortalized and leukaemia
cells with a Hes1- or RBPJ-null background. MLL–AF9-expressing Hes1-null AML cells
showed enhanced proliferation and ERK phosphorylation following FL stimulation. FLT3
inhibition efﬁciently abrogated the proliferation of MLL–AF9-induced Hes1-null AML cells.
Furthermore, an agonistic anti-Notch2 antibody induced apoptosis of MLL–AF9-induced
AML cells in a Hes1-WT but not a Hes1-null background. Furthermore, on referring to two
independent databases containing messenger RNA (mRNA) expression proﬁles, it has been
observed that the expression levels of FLT3 mRNA are negatively correlated with those of
Hes1 in AML patient samples. These observations demonstrate that Hes1 mediates tumour
suppressive roles of Notch signalling in AML development, probably by down-regulating
FLT3 expression [109].
1.6. Targeting FLT3: small molecule FLT3 inhibitors
AMLs with FLT3-ITD have higher relapse rates [110] and therefore inferior disease-free
and overall survivals [111], particularly in AMLs with larger ITD size [112], higher allelic
burden [113] and multiple ITDs [114]. Therefore, FLT3 inhibition has become a legitimate
therapeutic option, and clinical trials of FLT3 inhibitors in AML have been ongoing for a
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decade [115-117]. To date, more than 20 small molecule inhibitors against FLT3 have been
reported; some of them have been evaluated in clinical trials [118]. These include sorafenib
(BAY 43-9006), sunitinib (SU11248), midostaurin (PKC412), lestaurtinib (CEP-701),
tandutinib (MLN518), ABT-869, AKN-032, KW-2449, and AC220 [116,119-125].
Structurally, most of these inhibitors are heterocyclic compounds, inhibiting FLT3 activity
by competing with adenosine triphosphate (ATP) for binding to the ATP-binding pocket of
TKD [126]. Functionally, they are generally multikinase inhibitors. Their clinical activities
appear to be mediated by FLT3 inhibition, so that their efﬁcacies are limited to AML
carrying FLT3-ITD, and correlated with the inhibition of FLT3 phosphorylation and hence
its downstream signalling effectors [127-131]. Quizartinib (AC220), a second-generation
FLT3 inhibitor, has recently shown activity in AML in phase II clinical trials [132]. FLT3-
targeted antibody therapy (IMC-EB10) has just completed safety investigations in a phase 1
clinical trial (NCT00887926).
Although the inhibition of FLT3 may be achievable, clinical efﬁcacy is less than convincing,
being limited by the invariable leukaemia progression despite continuous treatment [116].
Comprehensive reviews on the mechanisms underlying drug resistance have been published
[41,116,133-140]. The proposed mechanisms include persistent activation of FLT3
signalling due to over-expression of FL and FLT3, activation of anti-apoptotic signals and
protection of leukaemia-initiating cells by the bone marrow niche [41,116,133-140].
Recently, there is compelling evidence that leukaemia clones carrying both ITD and TKD
mutations appear when resistance to FLT3 inhibitors occurs [41]. Interestingly, the
emergence of double ITD and TKD mutants can be recapitulated in vitro when FLT3-ITD+
leukaemia cell lines are treated with mutagens and FLT3 inhibitors [141]. Furthermore,
murine xenotransplantation models also suggest that, in some cases, FTL3-ITD and TKD
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double mutants actually exist in minute amounts before treatment with FLT3 inhibitors,
expand under the selection pressure of FLT3 inhibition and become the predominant
resistant clone(s) during the drug-refractory phase [142]. On the basis of this model of
clonal evolution, a multipronged strategy using more potent FLT3 inhibitors, and a
combinatorial approach targeting both FLT3-dependent and -independent pathways are
needed to improve outcome.
2. (−)-epigallocatechin-3-gallate (EGCG)
2.1. Tea catechins and cancer chemoprevention
Since ancient times, green tea (Camellia sinensis) has been considered to be a health-
promoting beverage. Green tea catechins (GTCs), including epicatechin (EC),
epigallocatechin (EGC), epicatechin-3-gallate (ECG) and (−)-epigallocatechin-3-gallate
(EGCG), are the major polyphenolic compounds of green tea (Fig. 3). The dry weights of
EC, ECG, EGC and EGCG are 792 ± 3, 1702 ± 16, 1695 ± 1 and 8295 ± 92 mg/100 g, in
green tea, and 240 ± 1, 761 ± 4, 1116 ± 24 and 1199 ± 0.12 mg/100 g, in black tea [143].
Several properties of GTCs have been implicated in their chemo-preventive effects, such as
their anti-oxidant [144], pro-oxidant [145] and anti-inflammatory [146] effects. Accounting
for 505-80% of the total GTCs content, EGCG is the most abundant catechin in green tea
and a traditional anti-oxidative free radical scavenger [144,147-149].
The anti-oxidant properties of EGCG are due to the presence of phenolic groups that are
sensitive to oxidation and can generate quinone [150]. The phenolic groups of EGCG serve
as electron donors that can give up an electron or a hydrogen atom, and the phenolic
molecule is capable of making an internal adjustment to stabilize the unpaired electron that
results from the loss [151]. EGCG can increase the levels of enzymes related to oxidative
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stress, including glutathione-S-transferase, glutamate cysteine ligase, superoxide dismutases,
and haeme oxygenase-1 (HO-1) both in vitro and in vivo [150,152]. EGCG-treated cancer
cells were found to have up-regulated PPARα activation that leads to the suppression of the
cytoprotective enzyme HO-1 and induction of cell death [153].
Lipopolysaccharide (LPS) is the important pathogenic substance that induces inflammatory
responses and angiogenesis, and it is a potent activator for MAPKs, which are expressed in
many inflammatory cells by stimulating the release of intermediary growth factors/cytokines
[154,155]. EGCG blocks LPS-induced production of several inflammatory factors, including
TNF-α, VEGF, MCP-1 and NO [156,157]. Moreover, EGCG effectively attenuates LPS -
induced activation and phosphorylation of MAPK pathways (ERK1/2 and p38) and NFκB
pathways (p-IkBα, p65 and p-p65) [156,157]. Moreover, EGCG inhibits the JAK/STAT
signalling cascade and suppresses the cytokine-induced expression of inducible nitric oxide
synthase and intercellular adhesion molecule-1, the key molecules involving in
inflammatory and tumourigenesis processes in cholangiocarcinoma [158].
Many studies have shown that the nuclear activities of EGCG inhibit inﬂammatory
responses that are usually accompanied by increased oxidative stress [159,160]. Thus, one
may claim that this anti-inﬂammatory action is mainly due to the direct anti-oxidant activity
of EGCG. However, it is not clear whether the anti-oxidative effects of EGCG are a major
mechanism underlying the anti-inﬂammatory actions of EGCG [159,160]. Interestingly,
EGCG-stimulated production of reactive oxygen species (ROS) causes the activation of NF-
κB and NF-E2-related factor 2 (Nrf2), leading to the increased expression of HO-1 and
glutathione [161,162]. Scavenging ROS by using various anti-oxidants abolishes EGCG-
stimulated induction of HO-1, while pre-treatment with EGCG has protective effects against
hydrogen peroxide-induced cytotoxicity [162]. Protective mechanisms used by EGCG to
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defend against oxidative stress may be secondary to the induction of various endogenous
anti-oxidant proteins [162].
2.2. Tea catechin and anti-tumours effects: the possible mechanisms
Several properties of GTCs have been implicated in their anti-cancer effects including anti-
mutagenic [152] and anti-angiogenic effects [154]. Among GTCs, EGCG is the most potent
catechins capable of inhibiting cell proliferation and inducing apoptosis in cancer cells
[144,147-149]. EGCG has been found to inhibit the development of cancer including lung
[163], prostate [164], colon [165], skin [166], and breast cancers [167].
A study involving breast cancer MCF7 and MDA-MB-231 cells showed that EGCG and a
pro-drug of EGCG (pEGCG, EGCG octaacetate) caused the hypomethylation of the human
telomerase reverse transcriptase (hTERT) gene via the inhibition of histone deacetylase
(HDAC) and histone acetyltransferase activity [168]. hTERT is a catalytic subunit of
telomerase, an important enzyme required for the maintenance of telomere length and
tumourigenesis. Demethylation of hTERT establishes a transcription-repressing
environment to prevent aberrant hTERT expression and leads to tumour suppression [168].
pEGCG was synthesized by the modulation of hydroxyl groups with peracetate groups to
enhance the bioavailability and stability of EGCG. The same research group also reported
that combining EGCG and the HDAC inhibitor trichostatin synergistically re-activated a
functional oestrogen receptor in MDA-MB-231 cells via altering the binding transcription
repressor complex pRb2/p130–E2F4/5–HDAC–DNMT1–SUV39H1 to the oestrogen
receptor α (ERα) promoter. This induction of ERα expression could sensitize ERα-negative
breast cancers to anti-hormone therapy [169].
EGCG increases hepatic autophagy by promoting the formation of autophagosomes,
increasing lysosomal acidification, and stimulating autophagic flux in hepatic cells and in
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vivo. EGCG also increases the phosphorylation of AMPK, one of the major regulators of
autophagy. Importantly, siRNA knockdown of AMPK has been reported to abrogate EGCG-
induced autophagy [170].
An important mechanism frequently overlooked in considering the biological effects of
EGCG and its derivatives is their potential interaction with tyrosine kinase oncoproteins that
are capable of initiating cell signalling [1,171-179]. EGCG inhibits the activation or
expression of some RTKs including epidermal growth factor receptor (ErbB) family
members: EGFR [171,172], HER2, HER3 [173,174], vascular endothelial growth factor
receptor (VEGFR) [175], PDGFR [176], fibroblast growth factor receptors (FGFR) [172]
and insulin-like growth factor 1 receptor (IGF-1R) [177]. Many possible mechanisms have
been proposed and tested to account for the effects of EGCG on RTKs.
Our research group’s previous studies have provided evidence that EGCG can directly target
the activation or expression of RTKs and their intracellular signalling pathways [1,178,179].
KIT has been an excellent molecular target for treating gastrointestinal stromal tumour
(GISTs) as it is over-expressed in almost all GISTs including imatinib-resistant cases
(approximately 95% GISTs over-express KIT) [180]. EGCG treatment inhibits the
proliferation of GIST-T1 cells and induces apoptosis by inhibiting the phosphorylation of
KIT and KIT downstream signalling molecules including MAPK and AKT [179]. The
phosphorylation of both focal adhesion kinase (FAK) and IGF-1R receptor was reported to
decrease after incubated these cell with EGCG in pancreatic cancer cells (AsPC-1 and
BxPC-3) [178]. In AML with mutant FLT3, EGCG has been reported to down-regulate
FLT3 expression and inhibit AKT, MAPK and STAT5 activities [1]. The possible
mechanism underlying this is explained in the Results and Discussion sections of this thesis.
Additional evidence from other research groups also indicate that EGCG suppresses the
24
expression of ErbB1 and ErbB2 proteins in mammary and epidermoid carcinoma cells, and
its inhibitory eﬀect on cell viability is mediated by the 67-kDa laminin receptor (67LR)
[171]. ErbB2 is known to be an internalization-resistant receptor; therefore, agents capable
of removing it from the membrane have therapeutic potential [181]. Furthermore, EGCG has
been shown to decrease the homoclustering of a lipid raft marker,
glycosylphosphatidylinositol-anchored GFP, and reduce the co-localization between lipid
rafts and 67LR [171]. Therefore, the main conclusion that can be derived is that the primary
target of EGCG is the lipid raft component of the plasma membrane followed by secondary
changes in the expression of ErbB proteins [171].
Recently, EGCG has been demonstrated as an inhibitor of Hsp90 [2] . EGCG acts by
binding at or near a C-terminal ATP binding site to inhibit dimerization and promote an
Hsp90 conformation that interferes with its chaperone activity for client proteins [2]. EGCG
also inhibits Hsp90 function by impairing its association with co-chaperones including
Hsc70 and p23 in the pancreatic cancer cell line MIA PaCa-2 [182]. In 2010, Tran et al.
reported that in MCF-7 human breast cancer cells, EGCG specifically inhibited the
expression of Hsp90 by inhibiting the promoter activity of Hsp90 [183].
EGCG has also been shown to competitively bind to the ATP binding site of IGF-1R and
block downstream signalling [184]. Sah et al. demonstrated that EGCG directly inhibits
ERK and AKT kinases in immortalized human cervical cells [185]. In addition, EGCG was
shown to play a role in the direct inhibition of the activation of ERK and MEK1 and of the
association between RAF with MEK1 as well as in the inhibition of AP-1 activity in H-Ras-
transformed mouse epidermal cells [186,187]. EGCG also exertes antiproliferative effects
on H-Ras-transformed rat intestinal epithelial cells [188]. These reports seem to be
significant when considering the prevention of colorectal cancer (CRC) by GTCs because
25
Ras (KRAS) gene mutations occur frequently in this malignancy [189]. Moreover, EGCG
administration through drinking water has been reported to significantly decrease small
intestinal tumour formation in adenomatous polyposis coli (APC)Min/1 mice, a recognized
model for human intestinal cancer, by reducing the expression of the phosphorylated form of
AKT and ERK proteins in small intestinal tumours [190]. EGCG administration through
drinking water also suppressed tumour formation in APCMin/1 mice by decreasing the levels
of basic fibroblast growth factor in small intestinal tissue samples [191]. These reports are
important because mutations of the APC gene, a tumour suppressor gene, are critically
implicated in human colorectal carcinogenesis [192].
Examining the cellular uptake and distribution of EGCG in cells has revealed that
approximately 75% radioactively labelled EGCG was found in the cytosolic compartment,
while some radioactivity was found in the membrane fraction [193]. This suggests that
EGCG at part directly binds to membrane components, including proteins and lipids. At the
cell surface, it directly interrupts the binding of EGF to VEGF or  interferes with the binding
of EGF to EGFR [172] thus preventing these growth factors from interacting with their
corresponding receptors and activating downstream signalling cascades [172,194]. However,
Weinstein et al. found that EGCG did not inhibit EGF binding when assays were performed
at 4°C, suggesting the involvement of others mechanism rather than evidence for
competition between EGCG and EGF [195]. In addition, EGCG may inhibit the activation
of RTKs by affecting the expression levels of their ligands. The expression levels of the
EGFR family ligands EGF and heregulin have been shown to be down-regulated by EGCG
treatment in CRC cells [196]. EGCG also decreases the levels of IGF-1, IGF-2, and VEGF,
which may be associated with decreased ERK and AKT activities, in CRC and
hepatocellular carcinoma cells [177,196,197].
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EGCG was found to modulate gene expression by inhibiting various transcription factors
including Sp1, NF-κB, AP-1, STAT1, STAT3 and FOXO1 [198-206]. The expression of
NF-κB and AP-1 is inhibited by EGCG in rats exposed to ischaemia-reperfusion (I/R) injury
[207]. EGCG inhibits STAT-1 to mediate its own protective effects in myocardial I/R injury
[205,208]. Inhibition of the transcription factor FOXO1 by EGCG leads to the suppression
of the basal levels of endothelin-1 and the differentiation of adipocytes [201,209]. Both
these mechanisms are linked to the activation of AKT that inhibits FOXO1 by direct
phosphorylation of FOXO1 and may have cardiometabolic implications [210,211].
2.3. Possible clinical applications of EGCG
EGCG possesses several potential clinical advantages compared to other traditional cancer
drugs as it is readily available in tea, a common beverage worldwide, inexpensive to isolate
and can be orally administered [212]. While traditional cancer drugs often harm some
healthy cells along with cancer cells and usually have toxic adverse effects [213], EGCG
appears to specifically target cancer cells, without harming healthy cells, and has an
acceptable safety profile [214]. These benefits support further development of EGCG as a
potentially useful anti-carcinogenic agent. A prospective cohort study with over 8000
individuals revealed that the daily consumption of green tea resulted in delayed cancer onset,
and a follow-up study of breast cancer patients found that stages I and II breast cancer
patients experienced a lower recurrence rate and longer disease-free period [215]. Moreover,
EGCG delivered in the form of a capsule (200 mg p.o.) for 12 weeks has been reported to be
effective in patients with human papilloma virus-infected cervical lesions [216].
The issues underlying the clinical application of EGCG include its poor stability and poor
oral bioavailability [217]. The octanol/buffer partition coefficient P of EGCG is 0.86 ± 0.03.
EGCG has high hydrophilicity and has difficulty in penetrating the cell membrane [218].
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Maximum catechin plasma concentration has been shown to be achieved 2 h after
consumption, and this was followed by rapid clearance [219,220]. Two factors considered to
be contributing to the limited oral bioavailability are sensitivity of catechin to the digestive
system and absorption barriers in the human gastrointestinal tract; both play a role in the
overall very poor intrinsic permeability of catechin and EGCG across the intestinal
epithelium [221]. Currently, using colloidal delivery systems such as liposomes [222-225],
micro-/nano-particles [226,227] or synthesized EGCG prodrugs such as peracetylated
EGCG (AcEGCG) [228] to increase lipophilicity and membrane permeability and to
improve the bioefficacy of EGCG are being investigated and have so far achieved promising
results.
28
STUDY OBJECTIVES
The main objectives of my study are:
1) Identifying determinants involved in the binding of FLT3 to Hsp90.
2) Identifying the mechanism by which EGCG down-regulates FLT3 expression.
3) Investigating the influence of EGCG on FLT3 promoter activity and FLT3
transcription, and
4) Evaluating the combined effects of EGCG and the FLT3 inhibitor PKC412 on AML
cells with mutant FLT3.
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MATERIALS AND METHODS
1. Cell lines and culture conditions
Experiments were conducted using human leukaemia cell lines: cell lines MOLM-13 and
MOLM-14 were established from a patient with acute monocytic leukaemia (M5a) carrying
t(9;11) [229], MV4-11 from a patient with AML carrying t(4;11) [230] and KOCL-48 from
an leukaemic infant carrying t(4;11) [231].
In MOLM-13 and MOLM-14 cells, two mutations within FLT3 exon 14 were detected: ITD
of 21 bps corresponding to codons Phe594-Asp600 and a novel missense nucleotide
substitution at the codon 599 (Tyr599Phe) [232,233]. Two types of mutations were located
on the same allele [233]. In MV4-11 cells, there are an ITD of 30 bps within FLT3 exon 14
corresponding to codons Tyr591-Asp600, and a Tyr591His mutation [232,233]. In KOCL-
48 cell line, FLT3-Asp835Glu mutation was detected [232]. The cell line THP-1 came from
the peripheral blood of a one-year old male infant with monocytic AML [234]. They do not
contain any known FLT3 mutations and have high endogenous FLT3-WT expression. These
cells were grown in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma-Aldrich,
Japan K.K., Tokyo, Japan) supplemented with 10% heat-inactivated feetal bovine serum
(FBS) (JRH Biosciences, Lenexa, KS, USA), 100 IU/ml penicillin, and 0.1 mg/ml
streptomycin (Nakalai Tesque, Kyoto, Japan) in a humidified incubator with 5% CO2 and
37°C.
The parental 32D cells were cultured in RPMI 1640 medium supplemented with 1 ng/ml IL-
3 (R&D Systems).
The 293FT and 293T cells were grown in Dulbecco’s modified Eagle’s medium (DMEM)
(Sigma-Aldrich, Japan K.K., Tokyo, Japan) supplemented with 10% FBS, 100 IU/ml
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penicillin, 0.1 mg/ml streptomycin, 1% sodium pyruvate (Wako Pure. Chemical Industries,
Osaka, Japan) and 1% L-glutamine (Nakalai Tesque, Kyoto, Japan) in a humidified
incubator with 5% CO2 and 37°C.
2. Plasmids constructs
The gene encoding full-length human FLT3-WT or FLT3-ITD [12 amino acids (a.a) were
inserted in JMD] was PCR-amplified using pAL-FLT3-WT or pAL-FLT3-ITD [kindly
provided by Dr. Masao Mizuki  (Osaka University Medical School, Osaka, Japan)] vectors
as templates using the forward primer FLT3(NotI)-
F:GCGGCCGCATGCCGGCGTTGGCG and the reverse primer FLT3(SpeI)-R:
ACTAGTCTACGAATCTTCGACCTG. The fragments were inserted into the NotI and SpeI
sites of pME-FLAG (a FLAG tag vector) to generate pME-FLAG–FLT3-WT or pME-
FLAG–FLT3-ITD12 vectors. The pME-FLAG–FLT3-D835V, pME-FLAG–FLT3-D835Y,
pME-FLAG–FLT3-D835N, pME-FLAG–FLT3-D835E, pME-FLAG–FLT3-D835H, pME-
FLAG–FLT3-WT-K644R, pME-FLAG–FLT3-ITD12-K644R and pME-FLAG–FLT3-
D835V-K644R vectors were created using the PrimeSTAR Mutagenesis Basal kit (Takara,
Tokyo, Japan) according to manufacturer’s instructions.
The pMKITNeo-FLT3-ITD7 (7 a.a. inserted in JMD) vector was kindly provided by Prof.
Toshio Kitamura (the University of Tokyo, Tokyo, Japan).
The FLT3 promoter was ampliﬁed using the forward primer 5′-
TAATCTCGAGCGTGGAATTCCTAGAATTGG-3′ and the reverse primer 5′-
ACGCAAGCTTGGCCTCCGGAGCCCGGGGT-3′. The ampliﬁed DNA fragments were
digested using XhoI and HindIII and inserted into the XhoI/HindIII site of the pGL4-10
plasmid (Promega, Tokyo, Japan).
All constructs were verified by restriction enzyme digestion and DNA sequencing.
31
3. Generation of 32D cells stably expressing FLT3-WT, FLT3-ITD or FLT3-
D835V
32D cells stably expressing FLT3-WT, FLT3-ITD or FLT3-D835V were generated using
pME-FLAG–FLT3-WT, pME-FLAG–FLT3-ITD12 or pME-FLAG–FLT3-D835V vectors,
respectively, using Lipofectamine 2000 (Invitrogen, Tokyo, Japan) according to
manufacturer’s instructions. These cells were selected in the presence of 0.8 mg/ml G418
(GIBCO BRL, Gaithersburg, MD, USA) for 2 weeks to establish 32D-FLT3-WT/FLT3-ITD
or FLT3-D835V.  32D transfectants expressing FLT3-ITD or FLT3-D835V were
maintained in RPMI 1640 medium containing 10% FBS in the absence of rmIL-3, while
32D-FLT3-WT-expressing cells were maintained in the presence of 10 ng/ml rhFL
(Peprotech, Tokyo, Japan).
4. Transient transfection
For transient expression in 293FT cells, cells were transfected with the indicated plasmids
using the Lipofectamine reagent, according to manufacturer’s instructions. Cells were
harvested 48 h after transfection for IP and immunoblotting.
5. Reagents
EGCG, EGC, ECG and catechin (purified powder) were generously gifted by Dr. Yukihiko
Hara (Japan), PKC412 was purchased from Sigma-Aldrich Japan K.K. (Tokyo, Japan) and
17-allylamino-17-desmethoxygeldanamycin (17-AAG) was purchased from Calbiochem
(Darmstadt, Germany). All reagents were dissolved in dimethylsulfoxide (DMSO) (Wako
Pure. Chemical Industries, Osaka, Japan). Control cells were cultured with the same
concentration of carrier DMSO as used in the highest dose of reagents. DMSO concentration
was kept under 0.1% for all experiments to avoid cytotoxicity.
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6. Cell proliferation assays
Cell proliferation was determined using the trypan blue dye exclusion test as previously
described [179]. Briefly, cells were seeded in 6-well plates at a density of 1 × 105 cells/ml in
the presence of different concentrations of EGCG, EGC, ECG and catechin for 72 h. After
treatment, 10 µl cell suspensions was mixed with 10 µl 0.4 % trypan blue, and viable cells
were manually counted using a haemocytometer. Results were calculated as the percentage
of values measured when cells were grown in the absence of reagents.
7. Western blot analysis
Cells were plated onto 10-cm dishes at a density of 1 × 105 cells/ml in the presence of
various concentrations of reagents. After incubation for indicated durations, cells were
collected and washed twice with phosphate buffered saline (PBS) (−). Cells were then
dissolved in a protein lysis buffer containing 5 mM ethylenediaminetetraacetic acid (EDTA),
50 mM NaF, 10 mM Na2H2P2O7, 0.01% Triton X-100, 5 mM N-2-hydroxyethyl piperazine-
N′-2-ethanesulfonic acid (HEPES), 150 mM NaCl, 1 mM Na3VO4, 1 mM
phenylmethylsulfonyl fluoride, and 75 µg/mL aprotinin on ice for 30 min with brief
vortexing 4 times with every 10 min. After centrifugation at 13,000 rpm at 4°C for 10 min,
total cell lysates were collected. Protein samples were electrophoresed through a
polyacrylamide gel and transferred to a Hybond-P membrane (Amersham, Buckinghamshire,
UK) by electro-blotting. After washing, the membrane was probed with antibodies, and
antibody binding was detected using BCIP/NBT substrate (Promega). The following
antibodies were obtained from Santa Cruz Biotechnology (CA, USA): FLT-3/FLK-2 (S-18)
(sc-480), STAT5 (C-17) (sc-835), Hsp90/ (F-8) (sc-13119) and survivin (sc-17779).
Phosphotyrosine-clone 4G10 antibody was purchased from Millipore (Tokyo, Japan). IgG
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from murine serum (I5381-5MG) and anti-actin (A2066) were from Sigma-Aldrich. FLT3
(8F2) and normal rabbit IgG (2729S), p44/42 MAPK (Erk1/2), phospho-p44/42 MAPK
(Thr202/Tyr204), AKT, phospho-AKT (Ser473), phospho-STAT5 (Tyr694), caspase-3,
caspase-9 (C9), XIAP and c-Myb (D2R4Y) antibodies were from Cell Signaling
Technology Japan (Tokyo, Japan). Anti-PARP antibody was from WAKO Chemicals
(Osaka, Japan).
8. Co-immunoprecipitation
For IP, cells were treated with EGCG for indicated hours and then harvested. Cells were
lysed as indicated above. Then, cell lysates were pre-clearned for reducing the amount of
non-specific contaminants with 50 l protein G-Sepharose 4 fast flow (Amersham
Pharmacia Biosciences, Tokyo, Japan) to a total volume of 500 l. After incubation on a
rotator for 1h at 4°C, supernatants were collected by centrifuging at 2500 ×g for 2–3 min at
4°C. A portion of the lysed samples was immunoprecipitated with FLT3 (F-8) or Hsp90
antibodies in an incubation buffer (10 mM Tris, pH 7.5; 5 mM MgCl2; 50 mM KCl and
0.01% Nonidet P-40) for 1 h or overnight at 4°C. Protein G-Sepharose 4 fast flow
(Amersham Pharmacia Biosciences, Tokyo, Japan) was then added for 1 h. The
immunoprecipitates were washed five times with Tris-buffered saline–Tween. The bound
proteins were resolved by SDS-PAGE and analysed by western blotting.
9. Determination of apoptosis
MOLM-13 and MOLM-14 cells were treated with EGCG, EGC or ECG for 16 h. Apoptotic
cells were evaluated by PE Annexin V (BD PharMingen) and analysed by FACS Calibur
(Becton, Dickinson). Collected data were analysed by FlowJo software (Tree Star) by Dr.
Makoto Yamagishi (the University of Tokyo, Tokyo, Japan).
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10. Morphologic assessment to detect apoptotic cells
For detecting fragmented nuclei and condensed chromatin, MOLM-13 cells at a density of 1
× 105 cells/ml were treated with 60 µM EGCG. After the indicated duration, cells were
harvested and fixed onto slides using a cytospin (Shandon, Shandon Southern Products Ltd.,
Cheshire, UK). Cells then were stained with Wright-Giemsa stain. Cell morphology was
observed under an inverted microscope.
11. Luciferase reporter assay
To check FLT3 promoter activity, each reporter (100 ng) plasmid and 5 ng Renilla luciferase
plasmid (internal control) were transfected into 293T cells (1 × 105 cells/well in 48-well
plates) by Lipofectamine, following manufacturer’s instructions. Luciferase activity was
measured using the Dual-Luciferase Reporter Assay System (Promega, Tokyo, Japan).
Promoter activities were expressed as the ratio of Fireﬂy luciferase to Renilla luciferase
activities.
12. Semi-quantitative reverse transcription-PCR.
Total RNA was extracted from cells treated with or without 60 µM EGCG for 8 h using
Sepasol (Nakalai). First-strand cDNA was synthesized from 1 µg of total RNA using
SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) and random
hexamers. A segment of FLT3 spanning exons 14 and 15 was amplified using primers
FLT3.1675F (5′-GACAACATCTCATTCTATGCAAC-3′) and FLT3.18R1 (5′-
TCTGAACTTCTCTTGAACCA-3′). The thermal cycling profile was 94°C for 2 min,
followed by 40 cycles of 94°C for 30 s, 55°C for 30 s, 72°C for 1 min and a final extension
at 72°C for 5 min. PCR products were separated by electrophoresis on a 1.5% agarose gel.
13. Isobologram
The dose-response interactions between EGCG and PKC412 in MOLM-13, MOLM-14,
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MV4-11 and KOCL-48 cells were evaluated at IC50 by the isobologram of Steel and
Peckham [235]. IC50 was defined as the reagent concentration that resulted in 50% cell
growth inhibition. The concept of isobologram has been described in detail elsewhere [235].
I used this method as it can cope with agents with unclear cytotoxic mechanisms and a
variety of dose-response curves of anti-cancer agents [235].
14. Statistical analysis
Data for isobologram were analysed as described elsewhere [236]. When the observed data
points of the combinations mainly fell in the area of supraadditivity or in the areas of
subadditivity and protection, i.e. the mean value of the data was smaller than that of the
predicted minimum values or greater than that of the predicted maximum values, the
combinations were considered to have a synergistic or antagonistic effect, respectively. To
determine whether the condition of synergism (or antagonism) truly existed, a statistical
analysis was performed. The Wilcoxon signed-ranks test was used for comparing the
observed data with the predicted minimum or maximum values for additive effects, which
were closest to the observed data. Probability (P) values of <0.05 were considered
significant. Combinations with P ≥ 0.05 were regarded as indicating additive to synergistic
or additive to antagonistic effects. The other data were analysed using Student’s t test.
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RESULTS
1. Destabilization of FLT3 by EGCG
1.1. Phosphorylation status of FLT3 is critical for its interaction with Hsp90
Mutant FLT3 has been demonstrated to be a bona fide client protein for Hsp90 in cell
models and primary AML cells [3,4,79,81,82]. On the other hand, in the literature, the
chaperoning of FLT3-WT by Hsp90 is still controversial topic [3,4]. To address whether
FLT3-WT requires Hsp90 as a molecular chaperone, I performed co-IP using AML cells
carrying FLT3-WT (THP-1), FLT3-ITD (MOLM-13; MV4-11) and FLT3-D835E (KOCL-
48 cells) as well as 293FT cells transiently over-expressing FLT3-WT or FLT3 mutations.
Cell lysates from these cells were co-immunoprecipitated with Hsp90 antibody and then
immunoblotted (IB) with FLT3 antibody. Notably, parental 293FT did not express FLT3
(Fig. 4A, lane 6). In agreement with previous reports, mutant FLT3s (FLT3-ITD and FLT3-
TKD) were shown to interact with Hsp90 in both AML cell lines and 293FT cells
expressing FLT3-ITD and FLT3-TKD (Fig. 4A), indicating that mutant FLT3s are client
proteins of Hsp90. Interestingly, endogenous FLT3-WT did not co-immunoprecipitate with
Hsp90 in THP-1 cells (Fig. 4A, lane 4) but ectopically-expressed FLT3-WT in 293FT
associated with Hsp90 (Fig. 4A, lane 7). Figure 4B shows that endogenous FLT3-WT in
THP-1 was not phosphorylated, whereas ectopically-expressed FLT3-WT in 293FT was
phosphorylated. Furthermore, constitutively de-phosphorylated form of FLT3/K644R did
not co-immunoprecipitate with Hsp90 in 293FT cells (Fig.4C, lane 2, 4 and 6). These data
indicated that Hsp90 selectively interacts with phosphorylated FLT3. Thus, it is highly
possible that the phosphorylation status of FLT3 is critical for its interaction with Hsp90.
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1.2. EGCG suppressed cell growth of FLT3-over-expressing AML cells
To examine whether EGCG can suppress the growth of AML cell lines, MOLM-13,
MOLM-14, MV4-11 and KOCL-48 cells were incubated either with DMSO alone (control)
or with different concentrations of EGCG for 72 h. Cell proliferation was evaluated using
the trypan blue exclusion test. The results showed that cells carrying mutant FLT3 (MOLM-
13, MOLM-14, MV4-11 and KOCL-48) were more sensitivity to EGCG in comparison with
THP-1 cells expressing FLT3-WT (Fig. 5A). Interestingly, 32D cells stably expressing
FLT3-WT were as sensitive to EGCG as those stably expressing mutant FLT3 (Fig. 5B).
Along with the data presented in Fig. 4B, these data indicated that the sensitivity of FLT3-
expressing cells to EGCG could be dependent on FLT3 phosphorylation status. Altogether,
EGCG exerted the anti-proliferation effects FLT3-phosphorylated cells.
1.3. EGCG induced apoptosis in FLT3-mutated AML cells
EGCG not only exerts a growth-inhibitory effect but also induces apoptosis in many cancer
cell lines [178,179]. Next, I demonstrated that EGCG induced apoptosis in FLT3-mutated
cell lines. First, Annexin V labeling analysis indicated that EGCG was signiﬁcantly
triggered apoptotic cell death in MOLM-14 cells (Fig. 6A). Second, I checked the
appearance of apoptotic markers after treatment with or without EGCG using western blot
analysis in MOLM-14 and MOLM-13 cells. The bands of cleaved-C9, cleaved-caspase-3
and cleaved-PARP were observed after 8 h treatment with EGCG (Fig. 6B and C).
Moreover, EGCG treatment caused suppressed expression of anti-apoptotic molecules such
as survivin and XIAP in MOLM-14 cells (Fig. 6B). Finally, nuclei fragmentation was
observed in MOLM-13 cells after 8 h treatment with 60 μM EGCG (Fig. 6D). Overall,
EGCG induced apoptosis in MOLM-14 and MOLM-13 cells.
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1.4. Down-regulation of FLT3 expression in EGCG-treated AML cells
FLT3 plays a pivotal role in the proliferation and survival of leukaemic cells. To investigate
whether EGCG treatment may affect the expression of FLT3, I analysed the expression of
FLT3 by western blotting in MOLM-13, MOLM-14, MV4-11 and KOCL-48 cells treated
with or without EGCG. Interestingly, the expression of FLT3 significantly decreased after
treating MOLM-13, MOLM-14, MV4-11 and KOCL-48 cells (FLT3-mutated cells) for 8 h
with different concentrations of EGCG (Fig. 7A). EGCG also suppressed FLT3 expression
in 293FT and 32D cells expressing FLT3-ITD and FLT3-D835V (Fig. 7B and C)
Interestingly, in THP-1 cells (FLT3-WT cells), the expression of FLT3 did not change even
at high EGCG concentrations (180 µM) (Fig. 7A). However, EGCG inhibited FLT3-WT
expression in 293FT and 32D cells expressing FLT3-WT as effectively as in those
expressing FLT3-ITD and FLT3-D835V in both dose- and time-dependent manners (Fig. 7B,
C and D). These data indicated that EGCG exerts its inhibitory effect on FLT3 expression.
1.5. EGCG disrupts interaction between FLT3 and Hsp90
EGCG has been demonstrated to be an inhibitor of Hsp90 [2]. In this study, I demonstrated
that phosphorylated FLT3 is a client of Hsp90 (Fig. 4) and that EGCG treatment affects
FLT3 expression (Fig. 7). These data suggest that Hsp90 is involved in down-regulating
FLT3 expression by EGCG. To confirm this hypothesis, total cell lysates of MOLM-13 and
293FT expressing FLT3-ITD or WT were collected after EGCG treatment and
immunoprecipitated with antibodies as shown in Fig. 8B. IP results showed that EGCG
treatment disrupted the association between Hsp90 with FLT3 and that it resulted in
reducing FLT3 expression (Fig. 8B). I have confirmed that Hsp90 expression was not
affected by EGCG treatment (Fig. 8A). The results confirmed aforementioned hypothesis.
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1.6. Phosphorylation status of FLT3 downstream molecules in EGCG-treated AML
cells
It is assumed that the down-regulation of FLT3 could lead to the inhibition of its activity,
and subsequently suppress the activity of its downstream molecules. To confirm this, I
measured the phosphorylation status of MAPK, AKT and STAT5 in MOLM-13, MOLM-14,
MV4-11, KOCL-48 and THP-1 cells after treatment with or without EGCG. The inhibition
of MAPK, AKT and STAT5 phosphorylation (p-MARK, p-AKT and p-STAT5) was
observed in MOLM-13, MOLM-14, MV4-11 and KOCL-48 cells after 8 h EGCG treatment
(Fig. 9). Although EGCG caused the suppression of cell growth in THP-1 cells (IC50  60
µM EGCG, Fig. 5A), phosphorylation of MAPK but not that of AKT or STAT5 decreased
at very high concentrations of EGCG (180 µM) (Fig. 9).
1.7. Growth inhibitory effects of EGC, ECG and catechin on FLT3-mutated AML
cells
In contrast to EGCG, studies on other GTCs such as ECG, EGC and catechin have rarely
been reported, particularly regarding their biological activity mechanisms. In this study, I
attempted to test the inhibitory effects of EGC, ECG and catechin on the growth of AML
cell lines. MOLM-13, MOLM-14, MV4-11 and KOCL-48 cells were incubated with either
DMSO alone (control) or different concentrations of reagents for 72 h. Cell proliferation
was evaluated using the trypan blue exclusion test. The results showed that EGC and ECG
significantly inhibited the cell proliferation of MOLM-13, MOLM-14, MV4-11 and KOCL-
48 cells in a dose-dependent manner (Fig. 10B and C). Whereas, catechin had no significant
affect cell growth inhibition (Fig. 10D). Among GTCs, EGCG along with EGC had stronger
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anti-cancer effects than others (EGCG  EGC > ECG > catechin). These data indicated that
the cell growth inhibitory activity of GTCs is polyphenol-dependent.
1.8. EGC and ECG induced apoptosis in FLT3-mutant AML cells.
Next, I demonstrated that EGC and ECG induced apoptosis in FLT3-mutated cell lines. I
investigated the appearance of apoptotic markers after EGC or ECG treatment by western
blotting in MOLM-14 cells. The bands of cleaved-C9, cleaved-caspase-3 and cleaved-PARP
were observed after 8 h EGC or ECG treatment (Fig. 11A). Moreover, EGC or ECG
treatment resulted in the inhibition of anti-apoptotic molecules such as survivin and XIAP in
MOLM-14 cells (Fig. 11A).
The results from PE-Annexin V staining (Fig. 11B) indicated that EGC and ECG induced
apoptosis in MOLM-14 cells treated with EGC or ECG. Overall, as with EGCG, EGC and
ECG also induced apoptosis in MOLM-14 cells.
1.9. Down-regulation of FLT3 expression and its downstream molecules in EGC-
and ECG-treated AML cells
To examine whether EGC and ECG suppress the expression of FLT3, MOLM-13, MOLM-
14, MV4-11 and KOCL-48 cells were treated with 100 µM EGC or 100/200 µM ECG for 8
h. Western blotting was performed to analyse the expression of FLT3. EGC-treated cells
showed not only the suppression of FLT3 expression, but also the suppression of
phosphorylation of MAPK, AKT and STAT5 (Fig. 12A). Similarly, the suppression of
FLT3 expression and phosphorylation of its downstream molecules were also observed in
ECG-treated cells (Fig. 12B).
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1.10. EGC and ECG suppressed FLT3 expression through Hsp90
Total cell lysates of MOLM-13 cells after EGC or EGC treatment were collected and
immunoprecipitated with antibodies as shown in Fig. 13. IP results showed that EGC and
ECG treatment disrupted the association between Hsp90 and FLT3 resulting in a reduction
of FLT3 expression (Fig. 13).
2. Suppression of FLT3 gene expression by EGCG
Next, I investigated the effects of EGCG on transcriptional regulation of FLT3. FLT3
mRNA level was evaluated in MOLM-13, MOLM-14, MV4-11, KOCL-48 and THP-1 cells
with or without EGCG (60 µM) treatment for 8 h. FLT3 mRNA level significantly reduced
on EGCG treatment in MOLM-13 cells (Fig. 14A). Using the luciferase-based FLT3
promoter reporter system, I also demonstrated that EGCG significantly inhibited FLT3
promoter activity (Fig. 14B).
3. Cytotoxic effects of EGCG in combination with PKC412
EGCG is one of the most studied polyphenol of green tea and shows the strongest anti-
cancer effects among other GTCs. In this study, I evaluated the combined effects of EGCG
and the FLT3 inhibitor PKC412. Interestingly, the results showed that the combination of
EGCG and PKC412 treatment strongly suppressed cell growth in MOLM-13, KOCL-48,
MV4-11 and MOLM-14 cells compared with EGCG or PKC412 treatment alone (Fig. 15).
However, the combined effects of simultaneous exposure to these differed among the cell
lines. In MOLM-13 and MOLM-14 cells, the combined data points fell within the envelope
of additivity. The mean values of the data (0.423 and 0.414, respectively) were greater than
those of the predicted minimum values (0.379 and 0.121, respectively) and smaller than
those of the predicted maximum values for the additive effect (0.766 and 0.549,
respectively; Table 1), indicating that simultaneous exposure to EGCG and PKC412
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produced an additive effect. In KOCL-48 and MV4-11 cells, the combined data points fell
mainly in the area of subadditivity, and the mean values of the data (0.887 and 0.803,
respectively) were greater than those of the predicted maximum additive values (0.410 and
0.579, respectively; Table 1), which were regarded as the antagonism effect.
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DISCUSSION
1. Phosphorylation status of FLT3 is critical for its interaction with Hsp90
In this study, I showed for the first time that FLT3 phosphorylation is required for its
interaction with Hsp90, regardless of FLT3-mutants or -WT (Fig. 4A and B). De-
phosphorylated FLT3 was unable to bind to Hsp90 (Fig. 4C). This study sheds light onto the
controversy surrounding the chaperoning of FLT3-WT by Hsp90. Although a study revealed
the association between FLT3-ITD and Hsp90 in 2002 [81], the interaction between FLT3-
WT and Hsp90 has not yet been clarified because of the lack of reliable evidence regarding
their interaction.
It is noteworthy that approximately 10%–15% AML patients display high FLT3-WT
expression [20]. The high levels of FLT3-WT receptor may promote constitutive activation
of the WT receptor in malignant cells [237]. In primary AML cells, the tyrosine
phosphorylated of over-expression FLT3-WT is rarely detected (3/27 patients with FLT3-
WT over-expression) [238]. The phosphorylation of FLT3-WT can be detected using
western blotting if its transcription level is up to 200,000 copies in 1 g RNA [238].
Therefore, it is too difficult to observe the Hsp90–FLT3-WT complex in blast cells of AML
patients [3]; however, this is achievable in cell lines over-expressing FLT3-WT, e.g.
SEMK2 cells [82]. SEMK2 cells have extremely high level of FLT3 expression and also
have a high level of phosphorylated FLT3 due to FLT3 locus amplification [237]. Therefore,
the phosphorylation status of FLT3-WT could endow it to form a complex with Hsp90 in
SEMK2 cells [82]. Moreover, the Hsp90–FLT3-WT complex has been detected in Ba/F3-
and 32D-expressing FLT3-WT cells [4,82]. In these cells, the growth of FLT3-WT-
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transduced Ba/F3 and 32D cells was conferred by FLT3-WT signalling (phosphorylated
FLT3) in the presence of FL ligand [239].
Interestingly, there is no controversy regarding the existence of an interaction between
FLT3-ITD or FLT3-TKD and Hsp90. Most reports have detected the binding complex
between mutant FLT3 and Hsp90 [1,3,4,79,81-83]. This might because mutant FLT3 is
closely associated with high expression levels of the FLT3 transcript [238] and is highly
activated [240].
Moreover, treating cells carrying FLT3-ITD with the FLT3 inhibitor sorafenib, which
inhibits FLT3-ITD activation, reduced the interaction between Hsp90 and FLT3 [4]. These
data indicated that FLT3 activity may be necessary for its interaction with Hsp90.
Previous reports have shown that the auto-phosphorylation of FLT3-WT caused by its over-
expression is inhibited by a potent FLT3 kinase inhibitor at the same sensitivity as that of
mutated FLT3 [238]. Other studies have provided clear evidence that high FLT3 expression
has a negative impact on overall and event-free survival in cytogenetically normal AML
patients lacking FLT3 mutations [21,238]. More recently, high transcript levels of FLT3
were associated with high risk of relapse in paediatric AML patients [241]. In this study, I
found that phosphorylated FLT3-WT was stabilized by Hsp90 and so was mutant FLT3 (Fig.
4). These data indicated that the over-expressed phosphorylated FLT3-WT possesses the
same clinical characteristics as those possessed by FLT3-ITD. Therefore, my findings
suggest that the over-expression of phosphorylated FLT3-WT might consider as the same
group with mutant FLT3.
Another study revealed that the association between Hsp90 and kinase proteins is
determined by the intrinsic stability of the kinase domain [79]. A two-step model for the
recognition of Hsp90 client proteins has been developed: first, CDC37 provides recognition
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of the kinase family and then, thermodynamic parameters determine client binding within
the family [79]. This model is consistent with known differences in the Hsp90 machinery
between prokaryotic and eukaryotic cells: prokaryotes do not have CDC37 and prokaryotic
Hsp90 does not chaperone kinases [242]; CDC37 is universally employed by Hsp90 for all
kinases [79]. In addition, the difference in thermal stability of the kinase constructs were
correlated with the interaction score of kinases to Hsp90, for example the Tm of Abl-WT
was 41.5°C; for the Abl-M472I mutant, it was 38.0°C, and for the Abl-M244I mutant, it was
45.4°C. The interaction score of them to Hsp90 have been reported to be 3.44, 1.72 and 6.88,
respectively [79]. Therefore, the thermodynamic stability but not the primary amino acid
sequence is the key determinant in the association of kinase clients with Hsp90 [79].
However, there is no evidence about the difference in thermal stability of the phosphorylated
and non-phosphorylated kinases particularly FLT3-WT, therefore to conclude whether
thermal stability is the only determinant for interaction between FLT3 and Hsp90 demands
further studies.
The majority of Hsp90-interacting tyrosine kinases are activating; mutant kinases with
decreased activity when compared to their WT counterparts have also been reported to be
Hsp90 clients. For example, B-RAF mutants that have reduced kinase activity displayed
enhanced sensitivity towards Hsp90 inhibitor-mediated degradation [243]. Similarly, kinase-
defective ERBB2 is an Hsp90 client, indicating that the activation status may not be the sole
determining factor for the recognition of client proteins by Hsp90 [244]. Interestingly, in my
experiments, the FLT3-WT/ITD/D835V-K644R mutations that lack the kinase activity did
not form complexes with Hsp90 (Fig. 4C). The limitation of my data is that the exact
determinant factor for the interaction between FLT3 and Hsp90 was not so clear due to the
confusion between the phosphorylation status and kinase activity of FLT3-K644R mutation.
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The FLT3 WT/ITD/D835V-K644R mutations lack kinase activity; thus, they could not
phosphorylate themselves. Further examinations need to be performed for confirmation.
Regardless of this limitation, the discrepancy in my observations once again indicated that
the determinant for binding to Hsp90 varies among different kinases. In case of FLT3, I
found that the phosphorylation status of FLT3 is a determinant for its interaction with Hsp90
(Fig. 4).
2. EGCG-regulated FLT3 expression: the possible mechanism
So far, my group has demonstrated that EGCG suppressed cell proliferation and caused
apoptotic cell death in GIST cells by the inhibition of KIT activity [179]. In this study, I
have reported that polyphenols of green tea caused apoptotic cell death in FLT3-mutated cell
lines (Fig. 5, 6, 10 and 11) by disrupting the interaction between Hsp90 and FLT3 (Fig. 8
and 13), leading to down-regulating the expression of FLT3 (Fig. 7 and 12) and ultimately
suppressing the activity of AKT, MAPK and STAT5 (Fig. 9 and 12).
Recent studies have indicated that RTKs are one of the critical targets of EGCG to inhibit
cancer cell growth. Previous studies have provided evidence that EGCG inhibited the
activation or expression of some RTKs including EGFR [172], HER2, HER3 [173,174],
VEGFR [175], PDGFR [245], FGFR [172] and IGF-1R [177,184]. In this study, I have
shown that EGCG suppressed FLT3 expression in cell lines harbouring FLT3 mutations
(Fig. 7) but not in THP-1 cells carrying FLT3-WT (Fig. 7A). However, in transient 293FT-
and 32D-stably expressing FLT3-WT, EGCG could inhibit FLT3-WT expression as
effectively as in those expressing FLT3-ITD and FLT3-D835V (Fig. 7 B, C and D).
EGCG has been demonstrated as a potential inhibitor of Hsp90 [2]. EGCG acts by binding
at or near a C-terminal ATP binding site to inhibit dimerization and promote an Hsp90
conformation that interferes with its chaperone activity for client proteins [2]. EGCG was
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shown to inhibit Hsp90 function by impairing Hsp90 association with co-chaperones
including Hsc70 and p23 in the pancreatic cancer cell line MIA PaCa-2 [182]. In 2010, Tran
et al. reported that EGCG specifically inhibits the expression of Hsp90 by inhibiting the
promoter activity of Hsp90 in MCF-7 human breast cancer cells [183]. Figure 8A shows that
EGCG did not affect the expression of Hsp90 but disrupted the interaction between Hsp90
and FLT3 (Fig. 8B). Regarding the insensitivity of EGCG in THP-1 cells, I assume that this
is mainly because FLT3-WT in THP-1 cells is not phosphorylated, and thereby, it is not able
to bind or has little binding effect to Hsp90 (Fig. 4). As a result, inhibition of Hsp90
function by EGCG could not effectively suppress FLT3 expression in THP-1 cells.
Another study found that short-term exposure to EGCG (within 2 h) inhibited EGF-induced
EGFR phosphorylation and its downstream signalling pathways but long-term exposure to
EGCG (> 24 h) decreased the expression levels of EGFR in human lung cancer cells [246].
Although, EGFR is not phosphorylated in A549 lung cancer cells, EGFR-WT has been
reported to interact with Hsp90 [247] and non-activated EGFR is inhibited by EGCG [246];
this indicates that EGCG tends to target Hsp90 functions rather than the activity of kinase
proteins. In the current study, short-term incubation (2 h) of MOLM-13 cells with 60 µM
EGCG did not significantly affect the phosphorylation of FLT3 (data not shown). Therefore,
reduction in kinase activation along with down-regulation of kinase protein levels on long-
term incubation with EGCG may be due to the dissociation of kinase clients from Hsp90 as
a result of Hsp90 function disruption by EGCG.
Recent studies have reported that EGCG can bind to its receptor 67LR, which is related to
cancerometastasis [248-252]. 67LR has been originally identified as a non-intergrin cell-
surface receptor for the extracellular matrix molecule laminin, over-expressed in various
cancer types [253]. Further, EGCG has been shown to induce cell death in HL-60 cells by
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inducing the 67LR/Akt/ eNOS/cGMP pathway [254]. However, Adachi et al. indicated that
EGCG may not directly bind to the cell surface receptor [195]. Moreover, when EGCG is
incubated with cells, 75% radioactively labelled EGCG was found in the cytosolic
compartment while some radioactivity was found in the membrane fraction [193]. This
suggests that the majority of EGCG permeates into the cytoplasm, where it directly interacts
with Hsp90 and other cytoplasmic molecules with a high possibility. Furthermore, only
EGCG but not EGC, ECG and other GTCs was shown to bind to 67LR [248]; my report
found that other GTCs have anti-tumour effects similar to those possessed by EGCG (Fig.
10). Therefore, 67LR is not the sole pathway for EGCG and other GTCs mediated its effect.
In contrast to EGCG, studies on ECG, EGC and EC have rarely been reported, particularly
pertaining to their biological activity mechanism. In my data, I for the first time suggest that
EGC and ECG also suppress FLT3 expression through inhibition of Hsp90 function in the
same manner as that by EGCG (Fig. 10-13).
The presence of the three adjacent hydroxyl (OH) groups in the molecule was suggested as a
key factor for enhancing the activity of EGCG in cancer cells [255,256]. Compounds having
a galloyl moiety show more potent activity [255]. In my study, I found that the cell growth
inhibitory activity of GTCs is structure-dependent (Fig. 10). The three adjacent OH groups
at position C-3′, 4′ and 5′ on the B ring of EGCG and EGC are more effective in suppressing
cell proliferation and inducing cell death than the two adjacent OH groups at C-3′ and 4′ of
ECG and catechin (Fig. 10 and 11). Moreover, the additional gallate moiety in ECG at C-3′
generally endows it with stronger anti-tumour effects than non-gallate compound such as
catechin (Fig. 10C and D).
Previous studies have shown that the anti-cancer effects of various GTCs vary depending on
the type and stage of malignancy [257,258]. Among GTCs, ECG is more effective than
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EGCG in suppressing the growth of gender-based carcinomas [257]. In contrast, recent
studies of human melanoma cell lines have indicated that EGCG is more potent than other
GTCs [258]. The results of my present investigation demonstrated that EGCG along with
EGC has stronger anti-cancer effects than other GTCs (EGCG  EGC > ECG > catechin) in
leukaemic cells (Fig. 10). These investigations indicated that anti-cancer action of various
GTCs vary with the type of malignancy and provides a model for tumour cell heterogeneity
based on susceptibility and resistance of tumour cells to different GTCs. Therefore, this
information is critical for undertaking chemopreventive or chemotherapeutic trials against
cancers.
To examine whether the down-regulation of FLT3 by EGCG was partly caused by reducing
its transcriptional level, a transient transfection study using the FLT3 promoter-reporter
construct was performed. A portion of the 5′-flanking region of FLT3 was cloned. As shown
in Fig. 14B, EGCG inhibited FLT3 promoter activity. However, the mRNA of FLT3 was
only significantly suppressed by EGCG in MOLM-13 cells but not in other cells (Fig. 14A).
3. Cytotoxic effects of EGCG in combination with PKC412
AML patients of all World Health Organization (WHO) subtypes other than t(15;17)
received 7+3 induction therapy that combines Ara-C (cytarabine; 7 days, continuous
intravenous) with an anthracycline such as daunorubicin or doxorubicin (adriamycin; 3 days,
intravenous push) [259]. Consolidation therapy followed in a cytogenetically-directed
manner, with the preferred treatment being either further intensive chemotherapy for good-
prognosis cases, such as Core Binding Factor rearrangements, allogenic stem-cell
transplantation for poor-prognosis cases such as those with complex cytogenetic, or a less
clearly deﬁned set of options for intermediate-prognosis cases, including normal cytogenetic
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AML [260-262]. Maintenance therapy for AML is not the current standard of care because
of a lack of efﬁcacy. Patients in relapse have limited treatment options, and outcome is
uniformly poor [263,264]. However, the high-dose cytarabine plus
anthracycline/anthracenedione treatment can become ineffective because of increased drug
resistance [265]. In some cases, chemotherapy has to be discontinued because of adverse
effects, which include bone marrow depression induced by indiscriminate killing of cells.
Most patients respond to induction therapy and enter remission with undetectable levels of
leukaemic blasts in the bone marrow. However, without further treatment, relapse is
inevitable for the vast majority of patients. Additional therapeutics, in particular those that
target known oncogenic signals in individual AML (personalized therapy), could potentially
delay or prevent relapse [266,267]. New treatment regimens are needed for relapse cases,
particularly in cases in which the leukaemia has developed resistance to chemotherapy. In
addition, even in those patients with relapsed leukaemia who remain sensitive to standard
chemotherapy, treatment may be complicated by toxicities associated with exceeding safe
cumulative doses of individual compounds, particularly anthracyclines [268]. This further
highlights the need for novel agents.
FLT3 inhibition has become a legitimate therapeutic option, and clinical trials of FLT3
inhibitors in AML have been ongoing for a decade [115-117]. To date, more than 20 small
molecule inhibitors against FLT3 have been reported; some of them have been evaluated in
clinical trials [118]. Although these inhibitors have been shown to be efficacious against
FLT3-activated cell lines in vitro and in preclinical efficacy models, clinical results to date
have been disappointing due to undesirable drug properties, dose-limiting toxicity and lack
of durable responses in patients with AMLs [119,269].
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One of the potential effective strategies for treating AML patients with FLT3 mutations is
combination therapy with inhibitors of FLT3, and alternative pathways [41] to target
multiple pathogenetic signalling pathways have been reported with a view to overcoming
resistance of the FLT3-ITD/TKD double mutant clones. For instance, resistance to FLT3
inhibition has been associated with the up-regulation of STAT5-mediated PIM (proviral
integration site for Moloney-murine leukaemia virus 1) expression, which is an anti-
apoptotic effector. Recent reports have demonstrated that PIM inhibition suppresses the
growth of FLT3-ITD+ cell lines and may function synergistically with FLT3 inhibitors in
vitro [270]. On the basis of the inhibitory activity of arsenic trioxide on ERK activity, a
downstream effector of FLT3 activation, combination of arsenic trioxide and the FLT3
inhibitor AG1296 has been evaluated [271]. The combination synergistically suppresses the
growth and induces apoptosis in FLT3-ITD+ cell lines. Although these therapeutic concepts
have yet to be tested in clinical trials, they provide proof-of-principle observations that
combinatorial targeting of multiple pathways may be exploited for the treatment of drug-
resistant double mutants. More candidate targets should be identiﬁed either by rational
design of regimen or high-throughput chemical screening.
The advantage of studying the effects of EGCG lies in knowing that the Japanese
customarily ingest EGCG in green tea every day. It is thought to be a non-toxic agent and is
now developing as a cancer preventive drug in the USA and Europe [272,273].
A number of publications have reported the effectiveness of using EGCG in combination
with other drugs [153,249]. For example, in many cancer cell types, EGCG was shown to
up-regulate the expression of PPARα [153]; therefore, the combination of EGCG and the
agonist of PPARα cloﬁbrate improved the anti-cancer effects of EGCG in comparison with
treatment using EGCG or clofibrate alone [153]. Other reports have found that PDE5, a
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cGMP negative regulator, was over-expressed in AML cell;, therefore, combination with
PDE5 inhibitor signiﬁcantly enhanced the anti-AML effects of EGCG at plasma levels, as
observed in clinical trials [253,274]. Moreover, phase I combination between EGCG with
standard chemo-radiation in surgically unresectable stage III non-small-cell lung cancer has
been reported [275].
In this study, I combined EGCG with PKC412 to evaluate their combined effects on FLT3-
mutated cell lines. The concentration of both drugs significantly reduced (Fig. 15) as
compared with using EGCG or PKC412 alone. For example, the concentration of EGCG
was 15 µM for reaching 50% cell-growth inhibition in MOLM-13 cells, however, when
combined with PKC412, it reduced to 10 µM (with 5 nM PKC412) and even 5 µM (with 7
nM PKC412). Similarly, the concentration of PKC412 alone for reaching 50% cell-growth
inhibition in MOLM-13 cells was 20 nM, however, when combined with EGCG, it
remarkably reduced to 5 nM (with 10 µM EGCG).
Taken together, the combination of EGCG and PKC412 fetched good but not so impressive
results; further candidates should be tested in combination with EGCG.
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CONCLUSION
In conclusion, I clarified that EGCG, EGC and ECG destabilized FLT3 by disrupting its
interaction with the molecular chaperone Hsp90 (Fig. 16). I also provided evidence that
EGCG suppresses FLT3 promoter activity and its transcription. Thus, EGCG is an effective
inhibitor of FLT3 at transcription and protein levels. Here I propose that EGCG can be a
useful therapeutic agent for AML patients particularly when used in combination with other
drugs such as the FLT3 inhibitor PKC412. My data suggest that EGCG is a promising
candidate for the treatment of AML or for combination with other drugs such as FLT3
inhibitors to improve the overall treatment efficacy.
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Figure 1. The inactive and active forms of FLT3
(A) The monomeric inactive FLT3 form that containing a ligand-binding extracellular
domain, a single transmembrane domain, a cytoplasmic juxtamembrane domain and a
kinase domain which split into two by a kinase insert. (B) FLT3-WT in dimerization
activated form upon binding to its ligand. (C) FLT3-ITD with auto-dimerization and
phosphorylation without FLT3 ligand binding. (D) FLT3-TKD with point mutation in
kinase domain that leads to constitutive activation.
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Figure 2. FLT3 signal transduction pathway
The binding of FLT3 ligand (FL) to its receptor leads to receptor dimerization and
activation of the intracellular kinase.Tyrosine kinase activation leads to phosphorylation of
multiple sites in the intracellular kinase moiety. The activated receptor recruits a number of
proteins in the cytoplasm including SHC and GRB2 to form a complex of protein-protein
interactions, leading to activation of a number of intracellular mediators including AKT,
MAPK, and STAT. Activated mediators interact with Hsp90, which protects them from
inactivation and chaperones the active mediators to the nuclear interphase, in which they
are released into the nucleus and act to mediate vital cellular functions including cell
growth, differentiation, apoptosis, DNA repair and proliferation [276].
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Figure 3. Chemical structure of the green tea catechins used in this study
Chemical structure of the green tea catechins. EGCG, (-)-epigallocatechin-3-gallate; EGC, (-)-
epigallocatechin; ECG, (-)-epicatechin-3-gallate; and catechin
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Figure 4. The phosphorylation status of FLT3 is needed for its binding to Hsp90
A. Total cell lysates of MOLM-13, MV4-11, KOCL-48, THP-1 and 293FT-transient
expressing different constructs of FLT3 were immunoprecipitated with Hsp90 antibody and
subjected to immunolot analysis with FLT3 and Hsp90 antibody. The levels of β-Actin
served as the loading control
B. KOCL-48; THP-1; 293FT-FLT3-WT and 293FT-FLT3-ITD cells at a density of 1 ×
105 cells/ml were IP with FLT3 antibody and subjected to immunolot analysis with 4G10
and FLT3 antibody. The levels of β -Actin served as the loading control.
C. 293FT-FLT3-WT/ITD/D835V-K644R cells at a density of 1 × 105 cells/ml were IP
with 4G10 or Hsp90 antibody and subjected to immunolot analysis with indicated antibody.
The levels of β -Actin served as the loading control.
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Figure 5. Effect of EGCG on cell proliferation of AMLs cell lines.
A. MOLM-13, MOLM-14, MV4-11, KOCL-48 and THP-1 cells at a density of 1 × 105
cells/ml were treated with indicated concentration of EGCG or DMSO alone as control for
72 h. The number of viable cells was counted after the trypan blue exclusion test. Results
were calculated as the percentage of the control values.
B. The number of 32D-tranfectant cells were counted after the trypan blue exclusion test.
C. Total cell lysate of 32D-parental and 32D-FLT3-ITD were subjected to western blot
analysis with indicated antibodies.
D. 32D-FLT3-ITD/D835V/WT cells were treated with indicated concentration of EGCG,
or DMSO alone as control for 72 h. The number of viable cells was counted after trypan
blue exclusion test. Results were calculated as the percentage of the control values.
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Figure 6. EGCG induced apoptosis in MOLM-14 and MOLM-13 cells.
MOLM-13 and MOLM-14 cells at a density of 1 × 105 cells/ml were treated with 60 µM
EGCG or DMSO alone as control for 16 h. MOLM-14 cells were staining with PE-
Annexin V and analysed by FACS Calibur. Collected data were analysed by FlowJo
software (A). Total cell lysates of MOLM-14 cells were subjected to western blot analysis
with indicated antibodies (B). Panel C showed the evidences of apoptosis induced by
EGCG treatment in MOLM-13 cells. To assess the nuclei, cells were fixed onto slides and
stained with Wright-Giemsa after treated with or without 60 µM EGCG, the morphology of
MOLM-13 cells observed under an inverted microscope. The arrow indicated that the
nuclei of MOLM-13 cells were fragmented by EGCG treatment (D).
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Figure 7. EGCG inhibited expression of FLT3 protein
A. MOLM-13, MOLM-14, MV4-11, KOCL-48 and THP-1 cells at a density of 1 × 105
cells/ml were treated with indicated concentration of EGCG or DMSO alone as control for 8
h. Total cell lysates were subjected to western blot analysis with indicated antibodies.
B and C. After 24 h transfected with FLT3-WT, FLT3-ITD, FLT3-D835V, 293FT cells were
treated with indicated concentration of EGCG or DMSO alone as control for indicated hours.
Total cell lysates were subjected to western blot analysis with indicated antibodies.
D. 32D-FLT3-ITD/D835V/WT cells at a density of 1 × 105 cells/ml were treated with 50
µM EGCG or DMSO alone as control for 8 h. Total cell lysates were subjected to western blot
analysis with indicated antibodies.
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Figure 8. EGCG dissociated the interaction between FLT3 and Hsp90 in 293FT-
expressing FLT3 and MOLM-13 cells
A. After 24 h transfected with FLT3-WT and FLT3-ITD, 293FT cells were treated with
200 µM concentration of EGCG or DMSO alone as control for indicated hours. Total cell
lysates were subjected to western blot analysis with indicated antibodies.
B. 293FT-FLT3-WT/ITD and MOLM-13 cells at a density of 1 × 105 cells/ml were
treated with 200 µM or 60 µM EGCG or DMSO alone as control for 4 or 8 h, respectively.
Total cell lysates were IP with anti-Hsp90. Precipitated protein were subjected to western
blot analysis with anti-FLT3 and anti Hsp90. The levels of -Actin served as the loading
control.
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Figure 9. Down-regulation of FLT3 downstream molecules in EGCG-treated AML
cells.
MOLM-13, MOLM-14, MV4-11, KOCL-48 and THP-1 cells at a density of 1 × 105
cells/ml were treated with indicated concentration of EGCG or DMSO alone as control
for 8 h. Total cell lysates were subjected to western blot analysis with indicated
antibodies.
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Figure 10. Effect of EGC, ECG and Catechin on cell proliferation of MOLM-13,
MOLM-14, MV4-11 and KOCL-48 cell lines.
MOLM-13, MOLM-14, MV4-11, KOCL-48 cells at a density of 1 × 105 cells/ml were
treated with indicated concentration of EGCG (A = figure 5A, for comparison), EGC (B),
ECG (C), catechin (D) or DMSO alone  as control for 72 s. The number of viable cells was
counted after the trypan blue exclusion test. Results were calculated as the percentage of
the control values.
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Figure 11. EGC and ECG induced apoptosis in MOLM-14 cells
MOLM-14 cells at a density of 1 × 105 cells/ml were treated with 100 µM EGC, 200 µM
ECG or DMSO alone as control for 16 h. Total cell lysates were subjected to western
blotting analysis with indicated antibodies (A) or staining with PE-Annexin V and analyzed
by FACS Calibur. Collected data were analysed by Flowjo software (B).
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Figure 12. Down-regulation of FLT3 expression and its downstream molecules in
EGC- and ECG-treated AML cells.
MOLM-13, MOLM-14, MV4-11 and KOCL-48 cells at a density of 1 × 105 cells/ml were
treated with indicated concentration of EGC (A) or ECG (B) or DMSO alone as control for
8 h. Total cell lysates were subjected to western blot analysis with indicated antibodies.
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Figure 13. EGC and ECG dissociated the interaction between FLT3 and Hsp90 in
MOLM-13 cells
MOLM-13 cells at a density of 1 × 105 cells/ml were treated with 100 µM EGC, 200 µM
ECG or DMSO alone as control for 8 h. Total cell lysates were immunoprecipitated with
anti-Hsp90. Precipitated protein were subjected to western blot analysis with indicated
antibodies.
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Figure 14. EGCG inhibited FLT3 promoter activity
A. Semi-quantitative reverse transcription-PCR, MOLM-13, MOLM-14, MV4-11,
KOCL-48 and THP-1 cells at a density of 1 × 105 cells/ml were treated with 60 µM EGCG
for an indicated duration. Total RNA was extracted and cDNA was synthesized to perform
PCR reaction with indicated primers.
B. The inhibition of EGCG on FLT3 promoter activity was analyzed by reporter assay (n
= 5, mean ± SD). Luciferase activities of reporter series were tested in a presence or
absence of 100 µM EGCG.
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Figure 15. Isobolograms of simultaneous exposure to EGCG and PKC412 in MOLM-
13, MOLM-14, MV4-11 and KOCL-48 cell lines.
The isobolograms shown are representative of at least three independent experiments. Each
point represents the mean value of at least three independent experiments. The combination
of EGCG with PKC412 showed additive effect (MOLM-13 and MOLM-14) and
antagonism effect (MV4-11 and KOCL-48).
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Figure 16. The mechanism of down-regulated FLT3 protein expression by GTP
The phosphorylated FLT3 bind to Hsp90. This association was disrupted by green tea
polyphenols (GTP) that lead to down-regulate FLT3 and its downstream signalling
molecules, finally induce apoptosis in AML overexpressing FLT3
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Table 1. Mean values of observed data and predicted minimum and maximum values
of the combination of EGCG and PKC412
Cell lines n Observed data
Predicted values for an
additive effect Effect
Minimum Maximum
MOLM-13 4 0.423 0.379 0.766 Additive
MOLM-14 5 0.414 0.121 0.549 Additive
MV4-11 5 0.803 0.205 0.410 Antagonism (<0.01)
KOCL-48 5 0.887 0.467 0.579 Antagonism (<0.01)
